Ana María López to lead medical oncology at Sidney Kimmel

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ana María López joined the Sidney Kimmel Cancer Center–Jefferson Health as the vice chair of medical oncology and chief of cancer services at the Sidney Kimmel Cancer Center–Washington Township.

López comes from the Huntsman Cancer Institute in Salt Lake City, where she was director of Cancer Health Equality, in addition to associate VP for Health Equity and Inclusion at the University of Utah Health; associate director of Collaboration and Engagement Services at the Utah Center for Clinical and Translational Sciences; and professor of medicine at UU School of Medicine.

She is an expert in breast and gynecological cancers, integrative medicine, telehealth and cancer disparities. Currently she is president of the Philadelphia-based American College of Physicians, which is the largest medical specialty organization in the United States. Additionally, her strong commitment to cancer disparities is reflected in her leadership of the American Society of Clinical Oncology committee on cancer disparities.

López will be based out of SKCC in Center City until the New Jersey site is remodeled. Once she moves into the new site, she will continue to collaborate with research and physician teams throughout the Sidney Kimmel Cancer Center Network and will still spend some days in Center City.

Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login